Equities Analysts Offer Predictions for ETON Q1 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for Eton Pharmaceuticals in a research note issued on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.09 per share for the quarter, down from their prior estimate of $0.12. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.14 EPS, FY2026 earnings at $0.85 EPS, FY2027 earnings at $1.13 EPS and FY2028 earnings at $1.28 EPS.

Separately, Craig Hallum boosted their price objective on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, October 28th.

Eton Pharmaceuticals Stock Down 4.2 %

ETON stock opened at $10.02 on Friday. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $11.11. The stock has a market capitalization of $258.92 million, a PE ratio of -45.55 and a beta of 1.25. The firm has a 50 day moving average of $7.40 and a 200 day moving average of $4.99.

Institutional Trading of Eton Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in Eton Pharmaceuticals during the third quarter valued at approximately $54,000. Jane Street Group LLC acquired a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $90,000. Renaissance Technologies LLC increased its holdings in shares of Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after purchasing an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in shares of Eton Pharmaceuticals in the 2nd quarter valued at $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Eton Pharmaceuticals by 86.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after buying an additional 30,167 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Opaleye Management Inc. purchased 11,248 shares of the business’s stock in a transaction on Monday, October 7th. The shares were bought at an average cost of $7.22 per share, with a total value of $81,210.56. Following the transaction, the insider now owns 2,730,000 shares of the company’s stock, valued at approximately $19,710,600. This trade represents a 0.41 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders bought 85,600 shares of company stock valued at $462,674 over the last quarter. 14.89% of the stock is currently owned by company insiders.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.